The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: Evidence from human genetic association studies and a mouse model of alcohol dependence

Translational Psychiatry

Volumn 5, Issue 6, 2015, Pages

  Suchankova, P ^a,b   Yan, J ^a,c   Schwandt, M L ^a   Stangl, B L ^a   Caparelli, E C ^d   Momenan, R ^a   Jerlhag, E ^b   Engel, J A ^b   Hodgkinson, C A ^a   Egli, M ^a   Lopez, M F ^e   Becker, H C ^e,f,g   Goldman, D ^a   Heilig, M ^a   Ramchandani, V A ^a   Leggio, L ^a,d,h  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^h BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 3174; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; UNCLASSIFIED DRUG; AC3174; ALCOHOL; CENTRAL DEPRESSANT AGENT; GLP1R PROTEIN, HUMAN; GLP1R PROTEIN, MOUSE; PEPTIDE;

ADULT; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLD SIGNAL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIATION; GENOTYPE; GLOBUS PALLIDUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOPHYSIOLOGY; POST HOC ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; AGONISTS; ALLELE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CASE CONTROL STUDY; DISEASE MODEL; DRINKING BEHAVIOR; DRUG EFFECTS; DRUG SELF ADMINISTRATION; FUNCTIONAL NEUROIMAGING; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; YOUNG ADULT;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ALLELES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DISEASE MODELS, ANIMAL; ETHANOL; FEMALE; FUNCTIONAL NEUROIMAGING; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLOBUS PALLIDUS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEUROPSYCHOLOGICAL TESTS; PEPTIDES; SELF ADMINISTRATION; YOUNG ADULT;

EID: 84990982111     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.68     Document Type: Article

References (51)

1. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): Hormone and neurotransmitter. Regul Pept 2005; 128: 97-107.
2. Pannacciulli N, Le DSNT, Salbe AD, Chen K, Reiman EM, Tataranni PA et al. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 2007; 35: 511-517.
3. Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005; 92: 798-806.
4. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-280.
5. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012; 153: 647-658.
6. Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013; 38: 1259-1270.
7. Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, Exendin- 4, decrease alcohol intake and reward. PLoS One 2013; 8: E61965.
8. Kendler KS, Myers J. Clinical indices of familial alcohol use disorder. Alcohol Clin Exp Res 2012; 36: 2126-2131.
9. Kareken DA, Liang T, Wetherill L, Dzemidzic M, Bragulat V, Cox C et al. A polymorphism in GABRA2 is associated with the medial frontal response to alcohol cues in an fMRI study. Alcohol Clin Exp Res 2010; 34: 2169-2178.
10. First MB Spitzer RL Gibbon M Williams JBW. Structured Clinical Interview for DSMIV- TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P), vol. 1/2007 revision. Biometrics Research, New York State Psychiatric Institute: New York, NY, USA, 2002.
11. Bierut LJ, Agrawal A, Bucholz KK, Doheny KF, Laurie C, Pugh E et al. A genomewide association study of alcohol dependence. Proc Natl Acad Sci USA 2010; 107: 5082-5087.
12. Yan J, Aliev F, Webb BT, Kendler KS, Williamson VS, Edenberg HJ et al. Using genetic information from candidate gene and genome-wide association studies in risk prediction for alcohol dependence. Addict Biol 2014; 19: 708-721.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
14. Zimmermann US, O'Connor S, Ramchandani VA. Modeling alcohol self-administration in the human laboratory. Curr Top Behav Neurosci 2013; 13: 315-353.
15. Stangl BL Zametkin M Hommer DW Ramchandani VA. The motivation for alcohol reward: Predictors of progressive-ration intravenous (IV) alcohol selfadministration in social drinkers. In: Alcoholism: Clinical and Experimental Research, 35th Annual Scientific Meeting of the Research Society on Alcoholism. Research Society on Alcoholism: San Francisco, CA, USA, 2012.
16. Ramchandani VA, Bolane J, Li TK, O'Connor S. A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res 1999; 23: 617-623.
17. Zimmermann US O'Connor S Ramchandani VA. Modeling alcohol selfadministration in the human laboratory. In: Sommer, WH, Spanagel, R (eds). Behavioral Neurobiology of Alcohol Addiction. Springer: Berlin-Heidelberg, Germany, 2013, pp 315-353.
18. Bjork JM, Smith AR, Chen G, Hommer DW. Mesolimbic recruitment by nondrug rewards in detoxified alcoholics: Effort anticipation, reward anticipation, and reward delivery. Hum Brain Mapp 2012; 33: 2174-2188.
19. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA et al. Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 2007; 141: 113-119.
20. Becker HC, Lopez MF. Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. Alcohol Clin Exp Res 2004; 28: 1829-1838.
21. Lopez MF, Becker HC. Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice. Psychopharmacology (Berl) 2005; 181: 688-696.
22. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005; 95: 221-227.
23. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
24. Grucza RA, Bierut LJ. Co-occurring risk factors for alcohol dependence and habitual smoking: Update on findings from the Collaborative Study on the Genetics of Alcoholism. Alcohol Res Health 2006; 29: 172-178.
25. John U, Meyer C, Rumpf H-J, Schumann A, Thyrian JR, Hapke U. Strength of the Relationship Between Tobacco Smoking, Nicotine Dependence and the Severity of Alcohol Dependence Syndrome Criteria in a Population-Based Sample. Alcohol Alcohol 2003; 38: 606-612.
26. Cox RW. AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996; 29: 162-173.
27. Chen G, Adleman NE, Saad ZS, Leibenluft E, Cox RW. Applications of multivariate modeling to neuroimaging group analysis: A comprehensive alternative to univariate general linear model. Neuroimage 2014; 99: 571-588.
28. Sobell LC Sobell MB. Timeline follow-back. In: Litten, RZ, Allen, JP (eds). Measuring Alcohol Consumption. Humana Press: Totowa, NJ, USA, 1992, pp 41-72.
29. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
30. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 2013; 24: 85-91.
31. Baumgartner I, Pacheco-López G, Rüttimann EB, Arnold M, Asarian L, Langhans W et al. Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 2010; 22: 557-563.
32. Parker JA, McCullough KA, Field BC, Minnion JS, Martin NM, Ghatei MA et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes (Lond) 2013; 37: 1391-1398.
33. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: Allosteric rescue of loss of function mutation. Mol Pharmacol 2011; 80: 486-497.
34. Sathananthan A, Man CD, Micheletto F, Zinsmeister AR, Camilleri M, Giesler PD et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: A pilot study. Diabetes Care 2010; 33: 2074-2076.
35. de Luis DA, Aller R, de la Fuente B, Primo D, Conde R, Izaola O et al. Relation of the rs6923761 gene variant in glucagon-like peptide 1 receptor with weight, cardiovascular risk factor, and serum adipokine levels in obese female subjects. J Clin Lab Anal 2014; 29: 100-105.
36. Ramsey TL, Brennan MD. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. Schizophr Res 2014; 160: 73-79.
37. Sheikh HI, Dougherty LR, Hayden EP, Klein DN, Singh SM. Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 980-983.
38. Heilig M, Goldman D, Berrettini W, O'Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 2011; 12: 670-684.
39. Prescott CA, Aggen SH, Kendler KS. Sex differences in the sources of genetic liability to alcohol abuse and dependence in a population-based sample of U. S. twins. Alcohol Clin Exp Res 1999; 23: 1136-1144.
40. Prescott CA, Kendler KS. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatry 1999; 156: 34-40.
41. Schlaepfer IR, Hoft NR, Ehringer MA. The genetic components of alcohol and nicotine co-addiction: From genes to behavior. Curr Drug Abuse Rev 2008; 1: 124-134.
42. Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One 2013; 8: E77284.
43. Hurt RD, Offord KP, Croghan IT, Gomez-Dahl L, Kottke TE, Morse RM et al. Mortality following inpatient addictions treatment. Role of tobacco use in a communitybased cohort. JAMA 1996; 275: 1097-1103.
44. Hong S, Hikosaka O. The globus pallidus sends reward-related signals to the lateral habenula. Neuron 2008; 60: 720-729.
45. Calder AJ, Beaver JD, Davis MH, van Ditzhuijzen J, Keane J, Lawrence AD. Disgust sensitivity predicts the insula and pallidal response to pictures of disgusting foods. Eur J Neurosci 2007; 25: 3422-3428.
46. Haber SN, Wolfe DP, Groenewegen HJ. The relationship between ventral striatal efferent fibers and the distribution of peptide-positive woolly fibers in the forebrain of the rhesus monkey. Neuroscience 1990; 39: 323-338.
47. Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci 2008; 28: 14311-14319.
48. Erreger K, Davis AR, Poe AM, Greig NH, Stanwood GD, Galli A. Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav 2012; 106: 574-578.
49. Mietlicki-Baase EG, Ortinski PI, Rupprecht LE, Olivos DR, Alhadeff AL, Pierce RC et al. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab 2013; 305: E1367-E1374.
50. Volkow ND, Wang GJ, Maynard L, Fowler JS, Jayne B, Telang F et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: A preliminary study. Psychiatry Res 2002; 116: 163-172.
51. Sen N. Epigenetic regulation of memory by acetylation and methylation of chromatin: Implications in neurological disorders, aging, and addiction. Neuromolecular Med 2014; 17: 97-110.